10x Genomics Announces Patent Litigation Settlement Agreement with Bruker
- On May 14, 2025, from Pleasanton, California, 10x Genomics, Inc. Announced that it has resolved all global patent disputes with Bruker Corporation through a negotiated settlement.
- The settlement follows extensive patent litigation and includes a $68 million payment by Bruker, made in equal quarterly installments between Q3 2025 and Q2 2026.
- In addition to payments, the settlement establishes ongoing royalties on Bruker's spatial biology products and global patent cross-licenses, with all legal proceedings withdrawn worldwide.
- Eric Whitaker, Chief Legal Officer, emphasized that the settlement highlights the strength of 10x's extensive patent holdings and the critical role their innovations play in advancing spatial biology.
- The outcome validates 10x Genomics' strategy to protect intellectual property, supports future investments, and helps advance innovations in single cell and spatial biology.
30 Articles
30 Articles

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker
PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and…
10x Settles Bruker, Vizgen Patent Lawsuits
10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition within the emerging single-cell and spatial genomics fields. On Wednesday of last week, Bruker said it became the second rival to settle with 10x in recent weeks, announcing that it had reached a “final settlement” intended to resolve their patent disputes and dismiss multiple lawsuits, while establis…
Coverage Details
Bias Distribution
- 83% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage